Subtopic Deep Dive
Hematopoietic Stem Cell Mobilization
Research Guide
What is Hematopoietic Stem Cell Mobilization?
Hematopoietic stem cell mobilization is the process of inducing hematopoietic stem cells (HSCs) from bone marrow niches into peripheral blood for efficient collection in transplantation procedures.
Mobilization primarily uses granulocyte colony-stimulating factor (G-CSF) alone or combined with plerixafor, a CXCR4 antagonist. Phase 3 trials by DiPersio et al. (2009) demonstrated plerixafor plus G-CSF superior to G-CSF alone in multiple myeloma (770 citations) and non-Hodgkin's lymphoma (670 citations). Consensus guidelines by Giralt et al. (2013, 397 citations) and Duong et al. (2014, 206 citations) standardize protocols for optimal stem cell yields.
Why It Matters
Effective mobilization ensures sufficient CD34+ cell yields for autologous transplantation, reducing graft failure and improving engraftment in multiple myeloma and lymphoma patients (DiPersio et al., 2009; 770 citations). Poor mobilizers face remobilization needs, impacting costs and outcomes, as analyzed by Pusic et al. (2008, 347 citations). Guidelines from Smith et al. (2015, 876 citations) and Giralt et al. (2013, 397 citations) guide clinical practice to enhance patient survival post-transplant.
Key Research Challenges
Poor Mobilizer Identification
Up to 20-30% of patients fail initial G-CSF mobilization due to age, prior therapy, or bone marrow pathology (Pusic et al., 2008, 347 citations). Predicting poor mobilizers requires biomarkers beyond CD34 counts. Giralt et al. (2013, 397 citations) recommend preemptive plerixafor for at-risk patients.
Optimizing Plerixafor Timing
Plerixafor dosing timing with G-CSF affects peak CD34+ yields variably across diseases (DiPersio et al., 2009, 770 citations). Phase 3 trials show superior collection but optimal intervals remain debated (DiPersio et al., 2009, 670 citations). Personalized kinetics monitoring is needed.
Cost-Effectiveness of Combinations
Plerixafor adds significant expense despite higher yields, challenging routine use (Duong et al., 2014, 206 citations). Consensus weighs risks of remobilization failures against costs (Giralt et al., 2013, 397 citations). Economic models for patient selection are lacking.
Essential Papers
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith, Kari Bohlke, Gary H. Lyman et al. · 2015 · Journal of Clinical Oncology · 876 citations
Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical Oncology convened ...
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee et al. · 2009 · Blood · 770 citations
Abstract This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mo...
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
John F. DiPersio, Ivana N. Micallef, Patrick J. Stiff et al. · 2009 · Journal of Clinical Oncology · 670 citations
Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's ly...
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt, Luciano J. Costa, Jeffrey Schriber et al. · 2013 · Biology of Blood and Marrow Transplantation · 397 citations
Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Robert J. Soiffer, Jennifer Le‐Rademacher, Vincent T. Ho et al. · 2011 · Blood · 349 citations
Abstract The success of reduced intensity conditioning (RIC) transplantation is largely dependent on alloimmune effects. It is critical to determine whether immune modulation with anti–T-cell antib...
Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation
Iskra Pusic, Shi Yuan Jiang, Scott Landua et al. · 2008 · Biology of Blood and Marrow Transplantation · 347 citations
Regulation of hematopoietic and leukemic stem cells by the immune system
Carsten Riether, Christian M. Schürch, Adrian F. Ochsenbein · 2014 · Cell Death and Differentiation · 235 citations
Reading Guide
Foundational Papers
Start with DiPersio et al. (2009, Blood, 770 citations) and DiPersio et al. (2009, JCO, 670 citations) for phase 3 plerixafor evidence in myeloma/NHL. Follow with Giralt et al. (2013, 397 citations) for optimization guidelines and Pusic et al. (2008, 347 citations) on remobilization failures.
Recent Advances
Smith et al. (2015, 876 citations) for ASCO WBC growth factor updates; Duong et al. (2014, 206 citations) for ASBMT peripheral blood guidelines incorporating plerixafor practices.
Core Methods
G-CSF (5-10 μg/kg/day x4-5 days); plerixafor (0.24 mg/kg SC evening dosing); apheresis when CD34+ ≥10/μL. CXCR4 antagonism disrupts SDF-1 niche retention (DiPersio et al., 2009).
How PapersFlow Helps You Research Hematopoietic Stem Cell Mobilization
Discover & Search
Research Agent uses searchPapers with 'plerixafor G-CSF mobilization multiple myeloma' to retrieve DiPersio et al. (2009, 770 citations), then citationGraph reveals downstream guidelines like Giralt et al. (2013). exaSearch uncovers plerixafor kinetics studies; findSimilarPapers expands to lymphoma trials by DiPersio et al. (2009, 670 citations).
Analyze & Verify
Analysis Agent applies readPaperContent to extract CD34+ yield data from DiPersio et al. (2009), then runPythonAnalysis with pandas computes mobilization success rates across trials. verifyResponse (CoVe) cross-checks claims against Pusic et al. (2008); GRADE grading scores evidence as high for phase 3 RCTs.
Synthesize & Write
Synthesis Agent detects gaps in poor mobilizer prediction from Pusic et al. (2008) and Giralt et al. (2013), flagging contradictions in plerixafor timing. Writing Agent uses latexEditText for protocol comparisons, latexSyncCitations integrates 10 papers, and latexCompile generates review sections; exportMermaid visualizes G-CSF/plerixafor pathways.
Use Cases
"Analyze CD34+ yields from plerixafor vs G-CSF trials in myeloma using Python stats"
Research Agent → searchPapers → Analysis Agent → readPaperContent (DiPersio 2009) → runPythonAnalysis (t-test on yields, matplotlib fold-change plots) → CSV export of p-values and confidence intervals.
"Write LaTeX review of mobilization guidelines with citations"
Research Agent → citationGraph (Giralt 2013, Duong 2014) → Synthesis → gap detection → Writing Agent → latexEditText (protocol table) → latexSyncCitations → latexCompile → PDF with formatted ASCO guidelines (Smith 2015).
"Find code for simulating HSC mobilization kinetics"
Research Agent → paperExtractUrls (DiPersio papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on ODE models for G-CSF/plerixafor dynamics → exportMermaid of kinetic diagrams.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ mobilization papers) → citationGraph → DeepScan (7-step: extract yields → verifyResponse → GRADE) → structured report on plerixafor efficacy. Theorizer generates hypotheses on poor mobilizer biomarkers from Pusic et al. (2008) patterns. Chain-of-Verification/CoVe ensures zero hallucinations in yield comparisons across DiPersio trials.
Frequently Asked Questions
What defines effective HSC mobilization?
Effective mobilization achieves ≥2 × 10^6 CD34+ cells/kg in ≤2 aphereses, per Giralt et al. (2013) consensus. DiPersio et al. (2009) phase 3 trials set benchmarks with plerixafor+G-CSF yielding 72% success vs 34% G-CSF alone.
What are main mobilization methods?
G-CSF alone (10 μg/kg/day), chemotherapy+G-CSF, or plerixafor (0.24 mg/kg) + G-CSF (Duong et al., 2014). Plerixafor blocks CXCR4/SDF-1 retention, rapidly increasing peripheral HSCs (DiPersio et al., 2009).
What are key papers on plerixafor?
DiPersio et al. (2009, Blood, 770 citations) for myeloma; DiPersio et al. (2009, JCO, 670 citations) for NHL. Smith et al. (2015, 876 citations) updates ASCO guidelines incorporating plerixafor.
What are open problems in mobilization?
Predicting poor mobilizers pre-apheresis (Pusic et al., 2008); cost-effective plerixafor use (Giralt et al., 2013); novel agents beyond CXCR4 blockade for resistant cases.
Research Hematopoietic Stem Cell Transplantation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hematopoietic Stem Cell Mobilization with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers